DEPO-TESTADIOL (estradiol cypionate; testosterone cypionate) by Pfizer is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the treatment of: 1. First approved in 1980.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
DEPO-TESTADIOL is a fixed-dose combination injectable containing estradiol cypionate and testosterone cypionate, designed for hormone replacement or hormonal management. The estradiol component acts through nuclear receptor binding to modulate reproductive function and secondary sexual characteristics, while the testosterone provides androgenic effects. This parenteral formulation uses cypionate esters to achieve prolonged absorption over several weeks from a single intramuscular injection.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team focus likely shifting toward generic transition planning and niche positioning.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on DEPO-TESTADIOL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on DEPO-TESTADIOL offers limited career growth due to its LOE-approaching status and minimal linked job openings; roles focus on managing decline and transitioning to generic competition. This is a stabilization role suitable for professionals seeking mature product management experience or preparing for a post-LOE market shift.